Script-to-Shelf™

SRI’s Script-to-Shelf™ Offering helps companies evaluate the impact of switching prescription (Rx) drugs to over-the-counter (OTC) status when the product nears the end of exclusivity. Their research combines physician and patient insights to estimate market share and revenue changes and identify optimal pricing for the new OTC product.

Multiple pricing models, including conjoint analysis, sequential monadic, and Van Westendorp, are used to ensure robust recommendations. SRI also uses scenario simulation tools for forecasting and click-and-highlight technology to identify what drives product choices.

Overstatement calibration and analog comparisons enhance the accuracy of adoption estimates. This integrated approach guides brands on pricing, sharing expectations, and marketing strategies for successful Rx-to-OTC transitions.